ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AZN Astrazeneca Plc

11,064.00
102.00 (0.93%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  102.00 0.93% 11,064.00 11,062.00 11,066.00 11,184.00 10,962.00 10,982.00 2,598,713 16:29:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 28.80 171.51B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,962p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,390.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £171.51 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 28.80.

Astrazeneca Share Discussion Threads

Showing 5701 to 5722 of 6150 messages
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older
DateSubjectAuthorDiscuss
08/7/2022
17:35
Next dividend

Declaration date 03 Aug 2022 (Wed)

Ex-div date 11 Aug 2022 (Thu)

Pay date 12 Sep 2022 (Mon)

waldron
08/7/2022
17:29
Starting to look toppy perhaps
waldron
08/7/2022
17:23
thought you were keeping AZN Dud and sold GSK
waldron
08/7/2022
17:03
I bailed today, held since 2009 and subsequent years.

If I get back to fitness, may invest again.

In all those years, never checked the divi?

I think 343% over 13yrs, not so bad.

Good luck

dudishes
06/7/2022
15:31
AZN paper is so rich...
diku
06/7/2022
12:11
Pound going to 1.15 analysts reckon, great news for FTSE 100 dollar earners bigger profits and dividends when converted.Astra, GSK, Hikma, Glencore etc.
montyhedge
05/7/2022
08:47
AstraZeneca PLC said Tuesday that it is buying TeneoTwo, Inc. for up to $1.27 billion in a deal that strengthens its haematological cancer pipeline.

The pharmaceutical giant said it will make an upfront payment of $100 million upon closing of the deal. A further payment of up to $805 million will be made dependent upon research-and-development milestones being reached and extra payments of up to $360 million could be payable to TeneoTwo shareholders based upon commercial-related milestones.

Astra said the acquisition is expected to close in the third quarter of this year and that it doesn't impact financial guidance for the year.



Write to Ian Walker at ian.walker@wsj.com



(END) Dow Jones Newswires

July 05, 2022 02:31 ET (06:31 GMT)

waldron
04/7/2022
10:05
gdr popish
ram376s
01/7/2022
08:53
Oxford BioMedica PLC said Friday that it has signed an extended agreement with AstraZeneca UK Ltd. for the use of its facility to produce AstraZeneca's Covid-19 vaccine.

The U.K. gene and cell therapy group said the new three-year agreement makes the vaccines manufacturing facility Oxbox available to AstraZeneca on an as-needed basis beyond 2022.

The deal represents an expansion of the original deal between the two companies in September 2020, which was originally expected to be complete in the last quarter of 2022, it added.

The company added that the company expects to recognize an aggregate revenue of 30 million pounds ($36.5 million) in the current financial year from AstraZeneca for the batches already manufactured in the first half of 2022.



Write to Michael Susin at michael.susin@wsj.com



(END) Dow Jones Newswires

July 01, 2022 02:56 ET (06:56 GMT)

adrian j boris
30/6/2022
09:02
This is bubble waiting to burst...think FTSE is artificially held up by AZN...
diku
29/6/2022
17:18
Time to sell do you reckon?
barrenwuffet1
29/6/2022
16:35
52 week high.....all time high.
steeplejack
27/6/2022
08:13
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.



Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT



(END) Dow Jones Newswires

June 27, 2022 02:40 ET (06:40 GMT)

the grumpy old men
23/6/2022
16:05
AstraZeneca's Wilson disease treatment shows promise in phase 3 trials

Thu, 23rd Jun 2022 15:59
Alliance News

(Alliance News) - AstraZeneca PLC on Thursday reported strong results

from phase III clinical trials for ALXN1840.

The Cambridge-based pharmaceutical company said the FoCus phase III trial of its once-daily, investigational oral medicine

ALXN1840 met its primary endpoint in the treatment of Wilson disease.

Wilson disease is an inherited condition which results in excess copper levels in the liver, brain and other organs. This leads to damage which can greatly impact those with the disease.

ALXN1840 showed copper mobilisation from tissues three-times greater than the standard of care arm.

Patients

experienced rapid copper mobilisation, with a response at four weeks, which was sustained through 48 weeks.

ALXN1840 is a novel molecule designed to bind to copper and remove it from the body's tissue and blood.

Shares in AZ were up 0.6% to 10,368.00 pence each in London on Thursday afternoon.

Two mechanistic trials in Wilson disease are underway, and AZ's rare disease group Alexion is working with global health authorities to submit the data for review.

By Elizabeth Winter; elizabethwinter@alliancenews.com

gibbs1
22/6/2022
07:33
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
buywell3
20/6/2022
20:41
The only thing that matters is a transfer of power from the west to the east. Short term gov. vs long term gov.
f56
17/6/2022
02:19
CWD is now in 27 states of the USA and spreading into Canada


A novel field test for CWD ( Prion Disease)
The University of Minnesota researchers develop novel, field-deployable test for CWD




However the spread of CWD continues unabated due to various stupid/illegal actions

buywell3
14/6/2022
14:14
Neutral another word for sell.
montyhedge
14/6/2022
11:03
Downgrade.

UBS cuts Astrazeneca to 'neutral' (buy) - price target 10,100 (10,500) pence

philanderer
08/6/2022
08:34
AstraZeneca PLC said Wednesday that trials on high-risk patients showed that the Evusheld drug provides significant protection against Covid-19.

The pharmaceutical company said that a single dose of Evusheld reduced the risk of progressing to severe Covid-19 or death by 50% in non-hospitalized patients with mild-to-moderate Covid-19. In those who received treatment within three days of symptom onset, the medicine reduced the risk by 88%.

The Tackle Phase 3 trial involved 903 adults across the U.S., Latin America, Europe and Japan.

"We are discussing the Tackle data with regulatory authorities and continue to progress submissions in both treatment and prophylaxis indications to help combat Covid-19 on all fronts," Executive Vice President Mene Pangalos said.



Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT



(END) Dow Jones Newswires

June 08, 2022 02:45 ET (06:45 GMT)

sarkasm
07/6/2022
09:36
Remember brokers have their own agendas for their clients to buy/sell into...is that chart showing as lower highs and lower lows?...
diku
07/6/2022
00:37
and this..

06/06/2022 | 07:38am EDT

Already positive, the research from JP Morgan and its analyst James Gordon still consider the stock as a Buy opportunity. The target price is unchanged and still at GBX 12000.

philanderer
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older

Your Recent History

Delayed Upgrade Clock